HealthDay on MSN9h
Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus Surgery
A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic ...
Pharmabiz3h
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Daily5d
GSK Depemokimab applications accepted for review in China, Japan for asthma with type 2 inflammation, CRSwNP
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
BioWorld2d
HMOX1 modulates oxidative stress in upper, lower airway diseases
Oxidative stress plays a critical role in the pathogenesis of upper and lower respiratory tract diseases, such as chronic rhinosinusitis with nasal polyps (CRSwNP), allergic rhinitis (AR), and asthma ...
pharmaphorum5d
FDA says no to AZ's Fasenra for nasal polyp indication
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
Yahoo Finance3d
AstraZeneca PLC (AZN)
WILMINGTON, Del., November 08, 2024--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that ...
Buy6d
Glaxosmithkline (GSK)
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...